Holt E A, Moulton L H, Siberry G K, Halsey N A
Department of International Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland.
J Infect Dis. 1993 Nov;168(5):1087-96. doi: 10.1093/infdis/168.5.1087.
Mortality was evaluated in 1972 children who had received measles vaccines at 6-11 months of age that were 10-fold (medium titer) or 100-fold (high titer) greater than standard titer. Mortality among boys did not differ by vaccine titer and was similar to mortality in children who received standard-titer vaccine. Girl recipients of high-titer vaccine had somewhat greater mortality than girls who received medium-titer vaccine (risk ratio = 1.71, 95% confidence interval = 0.91-3.24). Increased mortality was associated with high-titer vaccine for girls but not for boys (P = .04). There was no evidence of selection bias or preferential health care by sex that might explain the differential mortality. This mortality pattern has been noted in two other populations with high background infant and childhood mortality. The biologic basis for this effect on mortality has not been determined. Data from this and other studies have resulted in discontinuation of the use of high-titer measles vaccines.
对1972名6至11个月大时接种过麻疹疫苗的儿童的死亡率进行了评估,这些儿童接种的疫苗效价是标准效价的10倍(中等效价)或100倍(高效价)。男孩的死亡率在不同疫苗效价之间没有差异,且与接种标准效价疫苗的儿童的死亡率相似。接种高效价疫苗的女孩的死亡率略高于接种中等效价疫苗的女孩(风险比=1.71,95%置信区间=0.91-3.24)。女孩的死亡率增加与高效价疫苗有关,而男孩则不然(P=0.04)。没有证据表明存在可能解释死亡率差异的选择偏倚或按性别提供的优先医疗保健。在另外两个婴儿和儿童死亡率较高的人群中也注意到了这种死亡率模式。这种对死亡率产生影响的生物学基础尚未确定。来自本研究和其他研究的数据已导致停止使用高效价麻疹疫苗。